This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Emerging Cellular Therapies: T Cells and Beyond
joint with Lymphocytes and their Roles in Cancer
Organizer(s): Carl H. June, Marcela V. Maus and Bruce R. Blazar
Date: February 11 - 15, 2018
Location: Keystone Resort, Keystone, CO, USA
Sponsored by BioLegend, Inc., Editas Medicine, Gilead Sciences, Inc., Juno Therapeutics, Regeneron Pharmaceuticals, Inc., Sangamo Therapeutics, Inc. and Takeda Pharmaceutical Company Limited. This activity was supported by an educational grant from Celgene Corporation.
Summary of Meeting:
A new community of researchers is emerging that focuses on studying and developing cellular therapies against cancer and chronic infections. The field is advancing rapidly due to our deepening understanding of cell biology. New technologies permit efficient cell culture, gene transfer and genetic editing, enabling autologous and allogeneic cell therapy. With rapid development of CAR T cells, breakthrough FDA approval status, and fast-tracking clinical trials, competition is fierce in the biotechnology and pharmaceutical industries. Cell therapies with stem cells and T cells are in advanced clinical development that will enable widespread use for cancer and chronic infections such as HIV. Infusions of regulatory T cells (Tregs) have the potential to benefit patients with autoimmunity and transplantation. A goal of this conference is to bring together basic and translational scientists from these fields to identify current opportunities and challenges in cell therapies. Another goal is to bridge the fields of effector T cell and Treg cell therapies. The interdisciplinary features of this meeting should facilitate new collaborations and interactions between investigators who would not normally meet.
Scholarship Deadline: October 11 2017
Discounted Abstract Deadline: October 11 2017
Abstract Deadline: November 9 2017
Discounted Registration Deadline: December 13 2017
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
BioLegend, Inc.This activity was supported by an educational grant from Celgene CorporationEditas MedicineGilead Sciences, Inc.Juno TherapeuticsRegeneron Pharmaceuticals, Inc.Sangamo Therapeutics, Inc.Takeda Pharmaceutical Company Limited
We gratefully acknowledge additional support from these exhibitors at this conference:
Xcell Biosciences
We gratefully acknowledge additional support for this conference from:
AgilentBellicum PharmaceuticalsBio-Techne
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1 R13 CA224778-01
Funding for this conference was made possible (in part) by 1 R13 CA224778-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found